Global Respiratory Drugs Market 2016-2020 is latest research report adds on RnRMarketResearch.com, The analysts forecast global respiratory drugs market to grow at a CAGR of 6.48% during the period 2016-2020.
Asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and IPF are some of the major respiratory diseases. Among these, asthma and COPD are the most prevalent worldwide. Environmental pollution, changing lifestyles, and hereditary factors are some of the common causes of respiratory diseases. Intranasal corticosteroids, antihistamines, immunosuppressants, bronchodilators, and leukotriene antagonists are the respiratory medicines that are commonly used for the treatment of mild-to-moderate respiratory diseases. However, the choice of drug depends on the type and severity of the disease.
The report, Global Respiratory Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Purchase a Copy of the Report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=542958&utm_source=Fpro&utm_medium=Promotion&utm_campaign=SEO (Single User License - US $2500)
Key vendors : AstraZeneca, Boehringer Ingelheim, F.Hoffman-La Roche, GlaxoSmithKline, Merck, and Novartis.
Other prominent vendors: Abbott, Actavis, Afferent Pharmaceuticals, Alere, Almirall, Amgen, AptarGroup, Astellas, Aurobindo, Axis Shield, Baxter, Bayer, Biogen, Biotest, Bristol-Myers Squibb, Chiesi Farmaceutici, Cipla, Cytos, Dainippon Sumitomo, Dr. Reddy's Laboratories, FibroGen, Gilead Sciences, Glenmark, GNI Group Ltd, Horizon Pharma, ImmuneWorks, MediciNova, MedImmune, Mylan, Ono Pharmaceutical, Orchid Chemicals and Pharmaceuticals, Perrigo, Pfizer, Promedior, Prometheus, ProMetic Life Sciences, Ranbaxy, Rottapharm Madaus, Sanofi, Shionogi, Siemens Healthcare Diagnostics, Skyepharma, Sosei, Sunovion, Takeda Pharmaceutical , Teva, Theravance, United Therapeutics, Vectura, Vertex, and Zai Lab
Market Driver : Rise in prevalence of respiratory diseases
Market challenge : Unknown etiology of asthma and idiopathic pulmonary fibrosis
Market trend : Use of biologics
Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Objectives of asthma management
Exhibit 03: COPD: Prevalence in six EU countries
Exhibit 04: Management of COPD
Exhibit 05: Prevalence rate of allergic rhinitis in China
Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis
Exhibit 07: Non-pharmacological therapies for allergic rhinitis
Exhibit 08: Prevalence of cystic fibrosis by country 2014
Exhibit 09: Treatment options for IPF
Exhibit 10: Drugs approved by US FDA for respiratory diseases 2000-2015
Exhibit 11: Pipeline portfolio of major drug candidates for respiratory diseases
Exhibit 12: Global respiratory drugs market 2015-2020 ($ billions)
Exhibit 13: Global respiratory drugs market by diseases 2015
Exhibit 14: Five forces analysis and more..
Inquire for Discount on the Report at http://www.rnrmarketresearch.com/contacts/discount?rname=542958&utm_source=Fpro&utm_medium=Promotion&utm_campaign=SEO
Contactsales@rnrmarketresearch.com/ Call +1 888 391 5441 for further information on "Global Respiratory Drugs Market 2016-2020” report OR for any other market research and intelligence needs you may have for your business.